[Membre-smv] Interference Fièvre jaune et ROR

Jeu 16 Juin 20:05:42 CEST 2011

                       Bonjour Julian,

    L'étude  "Vaccin amaril et ROR" (Chronovac Voyageur) vient juste de 
commencer au Centre médical de l'Institut Pasteur ; d'autres centres de 
vaccinations internationales de la région parisienne vont y participer 
également.
     Son objectif principal est d'étudier la réponse au vaccin amaril 
chez des enfants ayant été vaccinés par le ROR moins de 28 jours et plus 
de 24 heures auparavant ; l'étude de la réponse au vaccin ROR fait 
partie des objectifs secondaires. A chaque enfant sont appariés deux 
témoins : l'un qui a reçu les deux vaccins (FJ et ROR) le même jour, 
l'autre, à plus de 28 jours d'intervalle.
        L'article que tu cites m'intéresse donc tout particulièrement : 
merci de nous en avoir fait part !

                      Très amicalement

                      Catherine Goujon
                      Centre médical de l'Institut Pasteur


> Bonjour a tous,
> Je savais qu'il avait un étude français "Vaccin FJ et ROR" en cours 
> (ou déjà fini ?)...
> Un article va aparaître en "Vaccine" (Article en Press).
> Des commentaires ?
> Dr Julian CORNAGLIA
> SMIT-CH Perpignan
>  
> Mutual interference on the immune response to yellow fever vaccine and 
> a combined vaccine against measles, mumps and rubella
> <http://www.sciencedirect.com/science?_ob=ShoppingCartURL&_method=add&_udi=B6TD4-530RP90-2&_acct=C000050221&_version=1&_userid=10&_ts=1307623625&md5=1cdb27b4230c21e2bdfb0fae183a3b95> 
>
>  
> *Juliana Romualdo Nascimento Silva^a 
> <http://www.sciencedirect.com/science/article/pii/S0264410X11007298#aff0005>^, 
> ^E-mail The Corresponding Author <mailto:julianarns at gmail.com>, Luiz 
> Antonio B. Camacho^a 
> <http://www.sciencedirect.com/science/article/pii/S0264410X11007298#aff0005>^, 
> ^Corresponding Author Contact Information 
> <http://www.sciencedirect.com/science/article/pii/S0264410X11007298#cor0005>^, 
> ^E-mail The Corresponding Author 
> <mailto:luiz.camacho at ensp.fiocruz.br>^, ^E-mail The Corresponding 
> Author <mailto:luiz.camacho at pq.cnpq.br>, Marilda M. Siqueira^b 
> <http://www.sciencedirect.com/science/article/pii/S0264410X11007298#aff0010>^, 
> ^E-mail The Corresponding Author <mailto:mmsiq at ioc.fiocruz.br>, Marcos 
> da Silva Freire^c 
> <http://www.sciencedirect.com/science/article/pii/S0264410X11007298#aff0015>^, 
> ^E-mail The Corresponding Author <mailto:freire at bio.fiocruz.br>, Yvone 
> P. Castro^d 
> <http://www.sciencedirect.com/science/article/pii/S0264410X11007298#aff0020>^, 
> ^E-mail The Corresponding Author <mailto:ivone.p at brturbo.com.br>, 
> Maria de Lourdes S. Maia^e 
> <http://www.sciencedirect.com/science/article/pii/S0264410X11007298#aff0025>^, 
> ^E-mail The Corresponding Author <mailto:lourdes.maia at bio.fiocruz.br>, 
> Anna Maya Y. Yamamura^f 
> <http://www.sciencedirect.com/science/article/pii/S0264410X11007298#aff0030>^, 
> ^E-mail The Corresponding Author <mailto:anna at bio.fiocruz.br>, 
> Reinaldo M. Martins^g 
> <http://www.sciencedirect.com/science/article/pii/S0264410X11007298#aff0035>^, 
> ^E-mail The Corresponding Author <mailto:Rmenezes at bio.fiocruz.br>, 
> Maria da Luz F. Leal^h 
> <http://www.sciencedirect.com/science/article/pii/S0264410X11007298#aff0040>^, 
> ^E-mail The Corresponding Author <mailto:Malu at bio.fiocruz.br> and 
> Collaborative Group for the Study of Yellow Fever Vaccines^1 
> <http://www.sciencedirect.com/science/article/pii/S0264410X11007298#fn0005>*
> ^a Departamento de Epidemiologia, Escola Nacional de Saúde Pública, 
> FIOCRUZ, Rua Leopoldo Bulhões, 1480, sala 820, Manguinhos, Rio de 
> Janeiro 21041-210, RJ, Brazil
> ^b Laboratório de Vírus Respiratórios e do Sarampo (LVRS), Instituto 
> Oswaldo Cruz, FIOCRUZ, Pavilhão Helio e Peggy Pereira, sala B105, Rua 
> Leopoldo Bulhões 1480, Manguinhos, Rio de Janeiro 21041-210, RJ, Brazil
> ^c Vice-Diretoria de Desenvolvimento Tecnológico de Bio-Manguinhos, 
> FIOCRUZ, Av. Brasil, 4365 – Manguinhos, Rio de Janeiro 21040-360, RJ, 
> Brazil
> ^d Programa de Imunizações da Secretaria Distrital de Saúde, SGAP, 
> Lote 6, Bloco G, Parque de Apoio, SIA, Brasilia 71-410-010, DF, Brazil
> ^e Assessoria Clínica, Bio-Manguinhos, FIOCRUZ, Av. Brasil, 4365 – 
> Manguinhos, Rio de Janeiro 21040-360, RJ, Brazil
> ^f Laboratorio de Tecnologia Virológica, Bio-Manguinhos, FIOCRUZ, Av. 
> Brasil, 4365 – Pavilhão Rocha Lima, Manguinhos, Rio de Janeiro 
> 21040-360, RJ, Brazil
> ^g Consultor Científico, Bio-Manguinhos, FIOCRUZ, Av. Brasil, 4365 – 
> Manguinhos, Rio de Janeiro 21040-360, RJ, Brazil
> ^h Vice-Diretoria de Qualidade de Bio-Manguinhos, FIOCRUZ, Av. Brasil, 
> 4365 – Manguinhos, Rio de Janeiro 21040-360, RJ, Brazil
> Received 21 November 2010; 
> revised 5 May 2011; 
> accepted 9 May 2011. 
> Available online 2 June 2011.
>
>
>       Abstract
>
> A randomized trial was conducted to assess the immunogenicity and 
> reactogenicity of yellow fever vaccines (YFV) given either 
> simultaneously in separate injections, or 30 days or more after a 
> combined measles–rubella–mumps (MRM) vaccine. Volunteers were also 
> randomized to YFV produced from 17DD and WHO-17D-213 substrains. The 
> study group comprised 1769 healthy 12-month-old children brought to 
> health care centers in Brasilia for routine vaccination. The 
> reactogenicity was of the type and frequency expected for the vaccines 
> and no severe adverse event was associated to either vaccine. 
> Seroconversion and seropositivity 30 days or more after vaccination 
> against yellow fever was similar across groups defined by YFV 
> substrain. Subjects injected YFV and MMR simultaneously had lower 
> seroconversion rates – 90% for rubella, 70% for yellow fever and 61% 
> for mumps – compared with those vaccinated 30 days apart – 97% for 
> rubella, 87% for yellow fever and 71% for mumps. Seroconversion rates 
> for measles were higher than 98% in both comparison groups. Geometric 
> mean titers for rubella and for yellow fever were approximately three 
> times higher among those who got the vaccines 30 days apart. For 
> measles and mumps antibodies GMTs were similar across groups. MMR's 
> interference in immune response of YFV and YFV's interference in 
> immune response of rubella and mumps components of MMR had never been 
> reported before but are consistent with previous observations from 
> other live vaccines. These results may affect the recommendations 
> regarding primary vaccination with yellow fever vaccine and MMR.
> ** 
> ------------------------------------------------------------------------
>
> _______________________________________________
> Membre-smv mailing list
> Membre-smv at medecine-voyages.fr
> http://lists.medecine-voyages.fr/cgi-bin/mailman/listinfo/membre-smv
>   

-------------- section suivante --------------
Une pièce jointe HTML a été nettoyée...
URL: <http://colossus02.mailclub.fr/pipermail/membre-smv/attachments/20110616/f03849c5/attachment.html>